References

1. Du, Z.; Lovly, C.M. Mechanisms of receptor tyrosine kinase activation in cancer. Molecular Cancer 2018, 17, 58, doi:10.1186/s12943-018-0782-4.
2. Plaza-Menacho, I.; Barnouin, K.; Barry, R.; Borg, A.; Orme, M.; Chauhan, R.; Mouilleron, S.; Martínez-Torres, R.J.; Meier, P.; McDonald, N.Q. RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements. Cell Rep 2016, 17, 3319–3332, doi:10.1016/j.celrep.2016.11.061.
3. Jmaeff, S.; Sidorova, Y.; Nedev, H.; Saarma, M.; Saragovi, H.U. Small-molecule agonists of the RET receptor tyrosine kinase activate biased trophic signals that are influenced by the presence of GFRa1 co-receptors. J. Biol. Chem. 2020, jbc.RA119.011802, doi:10.1074/jbc.RA119.011802.
4. Esseghir, S.; Todd, S.K.; Hunt, T.; Poulsom, R.; Plaza-Menacho, I.; Reis-Filho, J.S.; Isacke, C.M. A Role for Glial Cell–Derived Neurotrophic Factor–Induced Expression by Inflammatory Cytokines and RET/GFRα1 Receptor Up-regulation in Breast Cancer. Cancer Res 2007, 67, 11732–11741, doi:10.1158/0008-5472.CAN-07-2343.
5. Knowles, P.P.; Murray-Rust, J.; Kjær, S.; Scott, R.P.; Hanrahan, S.; Santoro, M.; Ibáñez, C.F.; McDonald, N.Q. Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain. J. Biol. Chem. 2006, 281, 33577–33587, doi:10.1074/jbc.M605604200.
6. Takahashi, M.; Ritz, J.; Cooper, G.M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985, 42, 581–588, doi:10.1016/0092-8674(85)90115-1.
7. Takahashi, M.; Cooper, G.M. ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol. Cell. Biol. 1987, 7, 1378–1385, doi:10.1128/mcb.7.4.1378.
8. Takahashi, M.; Asai, N.; Iwashita, T.; Isomura, T.; Miyazaki, K.; Matsuyama, M. Characterization of the ret proto-oncogene products expressed in mouse L cells. Oncogene 1993, 8, 2925–2929.
9. Runeberg‐Roos, P.; Saarma, P.M. Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Annals of Medicine 2007, 39, 572–580, doi:10.1080/07853890701646256.
10. Anders, J.; Kjar, S.; Ibáñez, C.F. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J. Biol. Chem. 2001, 276, 35808–35817, doi:10.1074/jbc.M104968200.
11. Nozaki, C.; Asai, N.; Murakami, H.; Iwashita, T.; Iwata, Y.; Horibe, K.; Klein, R.D.; Rosenthal, A.; Takahashi, M. Calcium-dependent Ret activation by GDNF and neurturin. Oncogene 1998, 16, 293–299, doi:10.1038/sj.onc.1201548.
12. van Weering, D.H.J.; Moen, T.C.; Braakman, I.; Baas, P.D.; Bos, J.L. Expression of the Receptor Tyrosine Kinase Ret on the Plasma Membrane Is Dependent on Calcium. J. Biol. Chem. 1998, 273, 12077–12081, doi:10.1074/jbc.273.20.12077.
13. Tahira, T.; Ishizaka, Y.; Itoh, F.; Sugimura, T.; Nagao, M. Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. Oncogene 1990.
14. Carter, M.T.; Yome, J.L.; Marcil, M.N.; Martin, C.A.; Vanhorne, J.B.; Mulligan, L.M. Conservation of RET proto-oncogene splicing variants and implications for RET isoform function. CGR 2001, 95, 169–176, doi:10.1159/000059341.
15. de Graaff, E.; Srinivas, S.; Kilkenny, C.; D’Agati, V.; Mankoo, B.S.; Costantini, F.; Pachnis, V. Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev 2001, 15, 2433–2444, doi:10.1101/gad.205001.
16. Tsai, V.W.W.; Husaini, Y.; Sainsbury, A.; Brown, D.A.; Breit, S.N. The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases. Cell Metab. 2018, 28, 353–368, doi:10.1016/j.cmet.2018.07.018.
17. Unsicker, K.; Spittau, B.; Krieglstein, K. The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev. 2013, 24, 373–384, doi:10.1016/j.cytogfr.2013.05.003.
18. Airaksinen, M.S.; Saarma, M. The GDNF family: Signalling, biological functions and therapeutic value. Nature Reviews Neuroscience 2002, 3, 383–394, doi:10.1038/nrn812.
19. Manié, S.; Santoro, M.; Fusco, A.; Billaud, M. The RET receptor: function in development and dysfunction in congenital malformation. Trends in Genetics 2001, 17, 580–589, doi:10.1016/S0168-9525(01)02420-9.
20. Bespalov, M.M.; Saarma, M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol. Sci. 2007, 28, 68–74, doi:10.1016/j.tips.2006.12.005.
21. Sidorova, Y.A.; Mätlik, K.; Paveliev, M.; Lindahl, M.; Piranen, E.; Milbrandt, J.; Arumäe, U.; Saarma, M.; Bespalov, M.M. Persephin signaling through GFRalpha1: the potential for the treatment of Parkinson’s disease. Mol. Cell. Neurosci. 2010, 44, 223–232, doi:10.1016/j.mcn.2010.03.009.
22. Baloh, R.H.; Tansey, M.G.; Lampe, P.A.; Fahrner, T.J.; Enomoto, H.; Simburger, K.S.; Leitner, M.L.; Araki, T.; Johnson, E.M.; Milbrandt, J. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 1998, 21, 1291–1302, doi:10.1016/s0896-6273(00)80649-2.
23. Yang, L.; Chang, C.-C.; Sun, Z.; Madsen, D.; Zhu, H.; Padkjær, S.B.; Wu, X.; Huang, T.; Hultman, K.; Paulsen, S.J.; et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nature Medicine 2017, 23, 1158–1166, doi:10.1038/nm.4394.
24. Mullican, S.E.; Lin-Schmidt, X.; Chin, C.-N.; Chavez, J.A.; Furman, J.L.; Armstrong, A.A.; Beck, S.C.; South, V.J.; Dinh, T.Q.; Cash-Mason, T.D.; et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nature Medicine 2017, 23, 1150–1157, doi:10.1038/nm.4392.
25. Emmerson, P.J.; Wang, F.; Du, Y.; Liu, Q.; Pickard, R.T.; Gonciarz, M.D.; Coskun, T.; Hamang, M.J.; Sindelar, D.K.; Ballman, K.K.; et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat. Med. 2017, 23, 1215–1219, doi:10.1038/nm.4393.
26. Hsu, J.-Y.; Crawley, S.; Chen, M.; Ayupova, D.A.; Lindhout, D.A.; Higbee, J.; Kutach, A.; Joo, W.; Gao, Z.; Fu, D.; et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 2017, 550, 255–259, doi:10.1038/nature24042.
27. Pierchala, B.A.; Milbrandt, J.; Johnson, E.M.; Jr Glial Cell Line-Derived Neurotrophic Factor-Dependent Recruitment of Ret into Lipid Rafts Enhances Signaling by Partitioning Ret from Proteasome-Dependent Degradation. The Journal of Neuroscience 2006, 26, 2777, doi:10.1523/JNEUROSCI.3420-05.2006.
28. Tsui, C.C.; Gabreski, N.A.; Hein, S.J.; Pierchala, B.A. Lipid Rafts Are Physiologic Membrane Microdomains Necessary for the Morphogenic and Developmental Functions of Glial Cell Line-Derived Neurotrophic Factor In Vivo. The Journal of Neuroscience 2015, 35, 13233, doi:10.1523/JNEUROSCI.2935-14.2015.
29. Murakumo, Y.; Jijiwa, M.; Asai, N.; Ichihara, M.; Takahashi, M. RET and neuroendocrine tumors. Pituitary 2006, 9, 179–192, doi:10.1007/s11102-006-0263-4.
30. Santoro, M.; Melillo, R.M.; Carlomagno, F.; Vecchio, G.; Fusco, A. Minireview: RET: Normal and Abnormal Functions. Endocrinology 2004, 145, 5448–5451, doi:10.1210/en.2004-0922.
31. Avantaggiato, V.; Dathan, N.A.; Grieco, M.; Fabien, N.; Lazzaro, D.; Fusco, A.; Simeone, A.; Santoro, M. Developmental expression of the RET protooncogene. Cell Growth & Differentiation 1994, 5, 305.
32. Pachnis, V.; Mankoo, B.; Costantini, F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 1993, 119, 1005–1017.
33. Attié‐Bitach, T.; Abitbol, M.; Gérard, M.; Delezoide, A.-L.; Augé, J.; Pelet, A.; Amiel, J.; Pachnis, V.; Munnich, A.; Lyonnet, S.; et al. Expression of the RET proto-oncogene in human Embryos. American Journal of Medical Genetics 1998, 80, 481–486, doi:10.1002/(SICI)1096-8628(19981228)80:5<481::AID-AJMG8>3.0.CO;2-6.
34. Kramer, E.R.; Liss, B. GDNF–Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease. FEBS Letters 2015, 589, 3760–3772, doi:10.1016/j.febslet.2015.11.006.
35. Mijatovic, J.; Airavaara, M.; Planken, A.; Auvinen, P.; Raasmaja, A.; Piepponen, T.P.; Costantini, F.; Ahtee, L.; Saarma, M. Constitutive Ret Activity in Knock-In Multiple Endocrine Neoplasia Type B Mice Induces Profound Elevation of Brain Dopamine Concentration via Enhanced Synthesis and Increases the Number of TH-Positive Cells in the Substantia Nigra. J. Neurosci. 2007, 27, 4799–4809, doi:10.1523/JNEUROSCI.5647-06.2007.
36. Jiang, Q.; Liu, F.; Miao, C.; Li, Q.; Zhang, Z.; Xiao, P.; Su, L.; Yu, K.; Chen, X.; Zhang, F.; et al. RET somatic mutations are underrecognized in Hirschsprung disease. Genetics in Medicine 2018, 20, 770–777, doi:10.1038/gim.2017.178.
37. Lin, L.F.; Doherty, D.H.; Lile, J.D.; Bektesh, S.; Collins, F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260, 1130–1132, doi:10.1126/science.8493557.
38. Durbec, P.; Marcos-Gutierrez, C.V.; Kilkenny, C.; Grigoriou, M.; Wartiowaara, K.; Suvanto, P.; Smith, D.; Ponder, B.; Costantini, F.; Saarma, M.; et al. GDNF signalling through the Ret receptor tyrosine kinase. Nature 1996, 381, 789–793, doi:10.1038/381789a0.
39. Schuchardt, A.; D’Agati, V.; Larsson-Blomberg, L.; Costantini, F.; Pachnis, V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994, 367, 380–383, doi:10.1038/367380a0.
40. Marcos, C.; Pachnis, V. The effect of the ret- mutation on the normal development of the central and parasympathetic nervous systems. Int. J. Dev. Biol. 1996, 40(Suppl 1), 137S-138S.Marcos, C.; Pachnis, V. The effect of the ret- mutation on the normal development of the central and parasympathetic nervous systems. Int. J. Dev. Biol. 1996, Suppl 1, 137S-138S.
41. Jain, S.; Golden, J.P.; Wozniak, D.; Pehek, E.; Johnson, E.M.; Milbrandt, J. RET Is Dispensable for Maintenance of Midbrain Dopaminergic Neurons in Adult Mice. J Neurosci 2006, 26, 11230–11238, doi:10.1523/JNEUROSCI.1876-06.2006.
42. Kramer, E.R.; Aron, L.; Ramakers, G.M.J.; Seitz, S.; Zhuang, X.; Beyer, K.; Smidt, M.P.; Klein, R. Absence of Ret Signaling in Mice Causes Progressive and Late Degeneration of the Nigrostriatal System. PLOS Biology 2007, 5, e39, doi:10.1371/journal.pbio.0050039.
43. Mijatovic, J.; Patrikainen, O.; Yavich, L.; Airavaara, M.; Ahtee, L.; Saarma, M.; Piepponen, T.P. Characterization of the striatal dopaminergic neurotransmission in MEN2B mice with elevated cerebral tissue dopamine. Journal of Neurochemistry 2008, 105, 1716–1725, doi:10.1111/j.1471-4159.2008.05265.x.
44. Mahato, A.K.; Kopra, J.; Renko, J.-M.; Visnapuu, T.; Korhonen, I.; Pulkkinen, N.; Bespalov, M.M.; Domanskyi, A.; Ronken, E.; Piepponen, T.P.; et al. Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo. Mov. Disord. 2020, 35, 245–255, doi:10.1002/mds.27943.
45. Mahato, A.K.; Renko, J.-M.; Kopra, J.; Visnapuu, T.; Korhonen, I.; Pulkkinen, N.; Bespalov, M.; Ronken, E.; Piepponen, T.P.; Voutilainen, M.; et al. GDNF receptor agonist supports dopamine neurons in vitro and protects their function in animal model of Parkinson’s; Neuroscience, 2019;
46. Chmielarz, P.; Er, Ş.; Konovalova, J.; Bandrés, L.; Hlushchuk, I.; Albert, K.; Panhelainen, A.; Luk, K.; Airavaara, M.; Domanskyi, A. GDNF/RET signaling pathway activation eliminates Lewy Body pathology in midbrain dopamine neurons. bioRxiv 2019, 752899, doi:10.1101/752899.
47. Dauer, W.; Przedborski, S. Parkinson’s Disease: Mechanisms and Models. Neuron 2003, 39, 889–909, doi:10.1016/S0896-6273(03)00568-3.
48. Horger, B.A.; Nishimura, M.C.; Armanini, M.P.; Wang, L.-C.; Poulsen, K.T.; Rosenblad, C.; Kirik, D.; Moffat, B.; Simmons, L.; Johnson, E.; et al. Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons. J. Neurosci. 1998, 18, 4929–4937, doi:10.1523/JNEUROSCI.18-13-04929.1998.
49. Zihlmann, K.B.; Ducray, A.D.; Schaller, B.; Huber, A.W.; Krebs, S.H.; Andres, R.H.; Seiler, R.W.; Meyer, M.; Widmer, H.R. The GDNF family members neurturin, artemin and persephin promote the morphological differentiation of cultured ventral mesencephalic dopaminergic neurons. Brain Res. Bull. 2005, 68, 42–53, doi:10.1016/j.brainresbull.2004.10.012.
50. Hoffer, B.J.; Hoffman, A.; Bowenkamp, K.; Huettl, P.; Hudson, J.; Martin, D.; Lin, L.F.; Gerhardt, G.A. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 1994, 182, 107–111, doi:10.1016/0304-3940(94)90218-6.
51. Bowenkamp, K.E.; Hoffman, A.F.; Gerhardt, G.A.; Henry, M.A.; Biddle, P.T.; Hoffer, B.J.; Granholm, A.-C.E. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. Journal of Comparative Neurology 1995, 355, 479–489, doi:10.1002/cne.903550402.
52. Beck, K.D.; Valverde, J.; Alexi, T.; Poulsen, K.; Moffat, B.; Vandlen, R.A.; Rosenthal, A.; Hefti, F. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995, 373, 339–341, doi:10.1038/373339a0.
53. Gash, D.M.; Zhang, Z.; Ovadia, A.; Cass, W.A.; Yi, A.; Simmerman, L.; Russell, D.; Martin, D.; Lapchak, P.A.; Collins, F.; et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380, 252–255, doi:10.1038/380252a0.
54. Kirik, D.; Rosenblad, C.; Bjorklund, A.; Mandel, R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 2000, 20, 4686–4700.
55. Kordower, J.H.; Emborg, M.E.; Bloch, J.; Ma, S.Y.; Chu, Y.; Leventhal, L.; McBride, J.; Chen, E.Y.; Palfi, S.; Roitberg, B.Z.; et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 2000, 290, 767–773, doi:10.1126/science.290.5492.767.
56. Oiwa, Y.; Yoshimura, R.; Nakai, K.; Itakura, T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson’s disease. Brain Res. 2002, 947, 271–283, doi:10.1016/s0006-8993(02)02934-7.
57. Runeberg-Roos, P.; Piccinini, E.; Penttinen, A.-M.; Mätlik, K.; Heikkinen, H.; Kuure, S.; Bespalov, M.M.; Peränen, J.; Garea-Rodríguez, E.; Fuchs, E.; et al. Developing therapeutically more efficient Neurturin variants for treatment of Parkinson’s disease. Neurobiol. Dis. 2016, 96, 335–345, doi:10.1016/j.nbd.2016.07.008.
58. Gill, S.S.; Patel, N.K.; Hotton, G.R.; O’Sullivan, K.; McCarter, R.; Bunnage, M.; Brooks, D.J.; Svendsen, C.N.; Heywood, P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9, 589–595, doi:10.1038/nm850.
59. Slevin, J.T.; Gerhardt, G.A.; Smith, C.D.; Gash, D.M.; Kryscio, R.; Young, B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005, 102, 216–222, doi:10.3171/jns.2005.102.2.0216.
60. Marks, W.J.; Ostrem, J.L.; Verhagen, L.; Starr, P.A.; Larson, P.S.; Bakay, R.A.; Taylor, R.; Cahn-Weiner, D.A.; Stoessl, A.J.; Olanow, C.W.; et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol 2008, 7, 400–408, doi:10.1016/S1474-4422(08)70065-6.
61. Lang, A.E.; Gill, S.; Patel, N.K.; Lozano, A.; Nutt, J.G.; Penn, R.; Brooks, D.J.; Hotton, G.; Moro, E.; Heywood, P.; et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59, 459–466, doi:10.1002/ana.20737.
62. Marks, W.J.; Bartus, R.T.; Siffert, J.; Davis, C.S.; Lozano, A.; Boulis, N.; Vitek, J.; Stacy, M.; Turner, D.; Verhagen, L.; et al. Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010, 9, 1164–1172, doi:10.1016/S1474-4422(10)70254-4.
63. Whone, A.L.; Boca, M.; Luz, M.; Woolley, M.; Mooney, L.; Dharia, S.; Broadfoot, J.; Cronin, D.; Schroers, C.; Barua, N.U.; et al. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease. J Parkinsons Dis 2019, 9, 301–313, doi:10.3233/JPD-191576.
64. Whone, A.; Luz, M.; Boca, M.; Woolley, M.; Mooney, L.; Dharia, S.; Broadfoot, J.; Cronin, D.; Schroers, C.; Barua, N.U.; et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease. Brain 2019, 142, 512–525, doi:10.1093/brain/awz023.
65. Bartus, R.T.; Johnson, E.M. Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: Where have we been and what have we learned? Neurobiol. Dis. 2017, 97, 156–168, doi:10.1016/j.nbd.2016.03.027.
66. Mahato, A.K.; Sidorova, Y.A. Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinson’s disease. Cell Tissue Res 2020, doi:10.1007/s00441-020-03227-4.
67. Datta, R.; Waheed, A.; Bonapace, G.; Shah, G.N.; Sly, W.S. Pathogenesis of retinitis pigmentosa associated with apoptosis-inducing mutations in carbonic anhydrase IV. Proc Natl Acad Sci U S A 2009, 106, 3437–3442, doi:10.1073/pnas.0813178106.
68. Schwartz, S.G.; Wang, X.; Chavis, P.; Kuriyan, A.E.; Abariga, S.A. Vitamin A and fish oils for preventing the progression of retinitis pigmentosa. Cochrane Database Syst Rev 2020, 6, CD008428, doi:10.1002/14651858.CD008428.pub3.
69. Muhammad Imran Qadir, S. Retinitis Pigmentosa: Pathophysiology and its Management. Fortune Journal of Health Sciences 2018, 1, 19–25.
70. Ferrari, S.; Di Iorio, E.; Barbaro, V.; Ponzin, D.; Sorrentino, F.S.; Parmeggiani, F. Retinitis Pigmentosa: Genes and Disease Mechanisms. Curr Genomics 2011, 12, 238–249, doi:10.2174/138920211795860107.
71. Dalkara, D.; Kolstad, K.D.; Guerin, K.I.; Hoffmann, N.V.; Visel, M.; Klimczak, R.R.; Schaffer, D.V.; Flannery, J.G. AAV Mediated GDNF Secretion From Retinal Glia Slows Down Retinal Degeneration in a Rat Model of Retinitis Pigmentosa. Mol Ther 2011, 19, 1602–1608, doi:10.1038/mt.2011.62.
72. McGee Sanftner, L.H.; Abel, H.; Hauswirth, W.W.; Flannery, J.G. Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. Mol. Ther. 2001, 4, 622–629, doi:10.1006/mthe.2001.0498.
73. Allocca, M.; Vicino, U.D.; Petrillo, M.; Carlomagno, F.; Domenici, L.; Auricchio, A. Constitutive and AP20187-Induced Ret Activation in Photoreceptors Does Not Protect from Light-Induced Damage. Invest. Ophthalmol. Vis. Sci. 2007, 48, 5199–5206, doi:10.1167/iovs.07-0140.Flachsbarth, K.; Jankowiak, W.; Kruszewski, K.; Helbing, S.; Bartsch, S.; Bartsch, U. Pronounced synergistic neuroprotective effect of GDNF and CNTF on axotomized retinal ganglion cells in the adult mouse. Exp. Eye Res. 2018, 176, 258–265, doi:10.1016/j.exer.2018.09.006.
74. Jmaeff, S.; Sidorova, Y.; Lippiatt, H.; Barcelona, P.F.; Nedev, H.; Saragovi, L.M.; Hancock, M.A.; Saarma, M.; Saragovi, H.U. Small-Molecule Ligands that Bind the RET Receptor Activate Neuroprotective Signals Independent of but Modulated by Coreceptor GFRα1. Mol. Pharmacol. 2020, 98, 1–12, doi:10.1124/mol.119.118950.Allocca, M.; Vicino, U.D.; Petrillo, M.; Carlomagno, F.; Domenici, L.; Auricchio, A. Constitutive and AP20187-Induced Ret Activation in Photoreceptors Does Not Protect from Light-Induced Damage. Invest. Ophthalmol. Vis. Sci. 2007, 48, 5199–5206, doi:10.1167/iovs.07-0140.
75. Flachsbarth, K.; Jankowiak, W.; Kruszewski, K.; Helbing, S.; Bartsch, S.; Bartsch, U. Pronounced synergistic neuroprotective effect of GDNF and CNTF on axotomized retinal ganglion cells in the adult mouse. Exp. Eye Res. 2018, 176, 258–265, doi:10.1016/j.exer.2018.09.006.Jmaeff, S.; Sidorova, Y.; Lippiatt, H.; Barcelona, P.F.; Nedev, H.; Saragovi, L.M.; Hancock, M.A.; Saarma, M.; Saragovi, H.U. Small-Molecule Ligands that Bind the RET Receptor Activate Neuroprotective Signals Independent of but Modulated by Coreceptor GFRα1. Mol. Pharmacol. 2020, 98, 1–12, doi:10.1124/mol.119.118950.
76. Fu, S.; Dong, S.; Zhu, M.; Sherry, D.M.; Wang, C.; You, Z.; Haigh, J.J.; Le, Y.-Z. Müller Glia Are a Major Cellular Source of Survival Signals for Retinal Neurons in Diabetes. Diabetes 2015, 64, 3554–3563, doi:10.2337/db15-0180.
77. Xu, B.; Zhang, H.; Zhu, M.; Le, Y.-Z. Critical Role of Trophic Factors in Protecting Müller Glia: Implications to Neuroprotection in Age-Related Macular Degeneration, Diabetic Retinopathy, and Anti-VEGF Therapies. Adv. Exp. Med. Biol. 2019, 1185, 469–473, doi:10.1007/978-3-030-27378-1_77.
78. Wu, L.; Xiao, P.; Li, Q.; Zhang, Z.; Wang, H.; Jiang, Q.; Li, L. Altered expression of AKT1 and P38A in the colons of patients with Hirschsprung’s disease. Pediatr Surg Int 2020, 36, 719–725, doi:10.1007/s00383-020-04653-9.
79. De Falco, V.; Carlomagno, F.; Li, H.; Santoro, M. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Practice & Research Clinical Endocrinology & Metabolism 2017, 31, 307–318, doi:10.1016/j.beem.2017.04.013.
80. Tomuschat, C.; Puri, P. RET gene is a major risk factor for Hirschsprung’s disease: a meta-analysis. Pediatr. Surg. Int. 2015, 31, 701–710, doi:10.1007/s00383-015-3731-y.
81. Porokuokka, L.L.; Virtanen, H.T.; Lindén, J.; Sidorova, Y.; Danilova, T.; Lindahl, M.; Saarma, M.; Andressoo, J.-O. Gfra1 Underexpression Causes Hirschsprung’s Disease and Associated Enterocolitis in Mice. Cellular and Molecular Gastroenterology and Hepatology 2019, 7, 655–678, doi:10.1016/j.jcmgh.2018.12.007.
82. Lui, V.C.H.; Samy, E.T.; Sham, M.H.; Mulligan, L.M.; Tam, P.K.H. Glial Cell Line–Derived Neurotrophic Factor Family Receptors Are Abnormally Expressed in Aganglionic Bowel of a Subpopulation of Patients with Hirschsprung’s Disease. Laboratory Investigation 2002, 82, 703–712, doi:10.1097/01.LAB.0000017364.13014.AE.
83. - IASP Available online: https://www.iasp-pain.org/Advocacy/GYAP.aspx?ItemNumber=5054 (accessed on Aug 12, 2020).
84. Yawn, B.P.; Wollan, P.C.; Weingarten, T.N.; Watson, J.C.; Hooten, W.M.; Melton, L.J. The prevalence of neuropathic pain: Clinical evaluation compared with screening tools in a community population. Pain Med 2009, 10, 586–593, doi:10.1111/j.1526-4637.2009.00588.x.
85. Schaefer, F.; van de Walle, J.; Zurowska, A.; Gimpel, C.; van Hoeck, K.; Drozdz, D.; Montini, G.; Bagdasorova, I.V.; Sorof, J.; Sugg, J.; et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J. Hypertens. 2010, 28, 1083–1090, doi:10.1097/HJH.0b013e328336b86b.Finnerup, N.B.; Attal, N.; Haroutounian, S.; McNicol, E.; Baron, R.; Dworkin, R.H.; Gilron, I.; Haanpaa, M.; Hansson, P.; Jensen, T.S.; et al. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol 2015, 14, 162–173, doi:10.1016/S1474-4422(14)70251-0.
86. Ossipov, M.H. Growth factors and neuropathic pain. Curr Pain Headache Rep 2011, 15, 185–192, doi:10.1007/s11916-011-0183-5.Schaefer, F.; van de Walle, J.; Zurowska, A.; Gimpel, C.; van Hoeck, K.; Drozdz, D.; Montini, G.; Bagdasorova, I.V.; Sorof, J.; Sugg, J.; et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J. Hypertens. 2010, 28, 1083–1090, doi:10.1097/HJH.0b013e328336b86b.
87. Blomqvist, K.J.; Viisanen, H.; Ahlström, F.H.G.; Jokinen, V.; Sidorova, Y.A.; Suleymanova, I.; Rauhala, P.V.; Kalso, E.A.; Lilius, T.O. Morphine-3-glucuronide causes antinociceptive cross-tolerance to morphine and increases spinal substance P expression. Eur. J. Pharmacol. 2020, 875, 173021, doi:10.1016/j.ejphar.2020.173021.Ossipov, M.H. Growth factors and neuropathic pain. Curr Pain Headache Rep 2011, 15, 185–192, doi:10.1007/s11916-011-0183-5.
88. Finnerup, N.B.; Attal, N.; Haroutounian, S.; McNicol, E.; Baron, R.; Dworkin, R.H.; Gilron, I.; Haanpaa, M.; Hansson, P.; Jensen, T.S.; et al. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol 2015, 14, 162–173, doi:10.1016/S1474-4422(14)70251-0.Blomqvist, K.J.; Viisanen, H.; Ahlström, F.H.G.; Jokinen, V.; Sidorova, Y.A.; Suleymanova, I.; Rauhala, P.V.; Kalso, E.A.; Lilius, T.O. Morphine-3-glucuronide causes antinociceptive cross-tolerance to morphine and increases spinal substance P expression. Eur. J. Pharmacol. 2020, 875, 173021, doi:10.1016/j.ejphar.2020.173021.
89. Bennett, D.L.; Boucher, T.J.; Armanini, M.P.; Poulsen, K.T.; Michael, G.J.; Priestley, J.V.; Phillips, H.S.; McMahon, S.B.; Shelton, D.L. The glial cell line-derived neurotrophic factor family receptor components are differentially regulated within sensory neurons after nerve injury. J. Neurosci. 2000, 20, 427–437.
90. Josephson, A.; Widenfalk, J.; Trifunovski, A.; Widmer, H.R.; Olson, L.; Spenger, C. GDNF and NGF family members and receptors in human fetal and adult spinal cord and dorsal root ganglia. J. Comp. Neurol. 2001, 440, 204–217, doi:10.1002/cne.1380.
91. Gardell, L.R.; Wang, R.; Ehrenfels, C.; Ossipov, M.H.; Rossomando, A.J.; Miller, S.; Buckley, C.; Cai, A.K.; Tse, A.; Foley, S.F.; et al. Multiple actions of systemic artemin in experimental neuropathy. Nat. Med. 2003, 9, 1383–1389, doi:10.1038/nm944.
92. Wang, R.; Rossomando, A.; Sah, D.W.Y.; Ossipov, M.H.; King, T.; Porreca, F. Artemin induced functional recovery and reinnervation after partial nerve injury. Pain 2014, 155, 476–484, doi:10.1016/j.pain.2013.11.007.
93. Boucher, T.J.; Okuse, K.; Bennett, D.L.; Munson, J.B.; Wood, J.N.; McMahon, S.B. Potent analgesic effects of GDNF in neuropathic pain states. Science 2000, 290, 124–127, doi:10.1126/science.290.5489.124.
94. Backonja, M.; Williams, L.; Miao, X.; Katz, N.; Chen, C. Safety and efficacy of neublastin in painful lumbosacral radiculopathy: a randomized, double-blinded, placebo-controlled phase 2 trial using Bayesian adaptive design (the SPRINT trial). Pain 2017, 158, 1802–1812, doi:10.1097/j.pain.0000000000000983.
95. Rolan, P.E.; O’Neill, G.; Versage, E.; Rana, J.; Tang, Y.; Galluppi, G.; Aycardi, E. First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica. PLoS ONE 2015, 10, e0125034, doi:10.1371/journal.pone.0125034.
96. Lippoldt, E.K.; Elmes, R.R.; McCoy, D.D.; Knowlton, W.M.; McKemy, D.D. Artemin, a glial cell line-derived neurotrophic factor family member, induces TRPM8-dependent cold pain. J. Neurosci. 2013, 33, 12543–12552, doi:10.1523/JNEUROSCI.5765-12.2013.
97. Lippoldt, E.K.; Ongun, S.; Kusaka, G.K.; McKemy, D.D. Inflammatory and neuropathic cold allodynia are selectively mediated by the neurotrophic factor receptor GFRα3. Proc. Natl. Acad. Sci. U.S.A. 2016, 113, 4506–4511, doi:10.1073/pnas.1603294113.
98. Usoskin, D.; Furlan, A.; Islam, S.; Abdo, H.; Lönnerberg, P.; Lou, D.; Hjerling-Leffler, J.; Haeggström, J.; Kharchenko, O.; Kharchenko, P.V.; et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nature Neuroscience 2015, 18, 145–153, doi:10.1038/nn.3881.
99. Clemmensen, C.; Müller, T.D.; Woods, S.C.; Berthoud, H.-R.; Seeley, R.J.; Tschöp, M.H. Gut-Brain Cross-Talk in Metabolic Control. Cell 2017, 168, 758–774, doi:10.1016/j.cell.2017.01.025.
100. Wang, A.; Huen, S.C.; Luan, H.H.; Yu, S.; Zhang, C.; Gallezot, J.-D.; Booth, C.J.; Medzhitov, R. Opposing Effects of Fasting Metabolism on Tissue Tolerance in Bacterial and Viral Inflammation. Cell 2016, 166, 1512-1525.e12, doi:10.1016/j.cell.2016.07.026.
101. Quartu, M.; Serra, M.P.; Boi, M.; Ferretti, M.T.; Lai, M.L.; Del Fiacco, M. Tissue distribution of Ret, GFRalpha-1, GFRalpha-2 and GFRalpha-3 receptors in the human brainstem at fetal, neonatal and adult age. Brain Research 2007, 1173, 36–52, doi:10.1016/j.brainres.2007.07.064.
102. Mulligan, L.M. GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential. Front. Physiol. 2019, 9, doi:10.3389/fphys.2018.01873.
103. Santoro, M.; Carlomagno, F. Central Role of RET in Thyroid Cancer. Cold Spring Harb Perspect Biol 2013, 5, doi:10.1101/cshperspect.a009233.
104. Eng, C. Multiple Endocrine Neoplasia Type 2. In GeneReviews®; Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J., Stephens, K., Amemiya, A., Eds.; University of Washington, Seattle: Seattle (WA), 1993.
105. Runeberg-Roos, P.; Virtanen, H.; Saarma, M. RET(MEN 2B) is active in the endoplasmic reticulum before reaching the cell surface. Oncogene 2007, 26, 7909–7915, doi:10.1038/sj.onc.1210591.
106. Regad, T. Targeting RTK Signaling Pathways in Cancer. Cancers (Basel) 2015, 7, 1758–1784, doi:10.3390/cancers7030860.
107. Sangwan, V.; Park, M. Receptor tyrosine kinases: role in cancer progression. Curr Oncol 2006, 13, 191–193.
108. Nikiforov, Y.E. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 2002, 13, 3–16, doi:10.1385/ep:13:1:03.
109. Thomas, G.A.; Bunnell, H.; Cook, H.A.; Williams, E.D.; Nerovnya, A.; Cherstvoy, E.D.; Tronko, N.D.; Bogdanova, T.I.; Chiappetta, G.; Viglietto, G.; et al. High Prevalence of RET/PTC Rearrangements in Ukrainian and Belarussian Post-Chernobyl Thyroid Papillary Carcinomas: A Strong Correlation between RET/PTC3 and the Solid-Follicular Variant. J Clin Endocrinol Metab 1999, 84, 4232–4238, doi:10.1210/jcem.84.11.6129.
110. Kohno, T.; Ichikawa, H.; Totoki, Y.; Yasuda, K.; Hiramoto, M.; Nammo, T.; Sakamoto, H.; Tsuta, K.; Furuta, K.; Shimada, Y.; et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012, 18, 375–377, doi:10.1038/nm.2644.
111. Lipson, D.; Capelletti, M.; Yelensky, R.; Otto, G.; Parker, A.; Jarosz, M.; Curran, J.A.; Balasubramanian, S.; Bloom, T.; Brennan, K.W.; et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012, 18, 382–384, doi:10.1038/nm.2673.
112. Ju, Y.S.; Lee, W.-C.; Shin, J.-Y.; Lee, S.; Bleazard, T.; Won, J.-K.; Kim, Y.T.; Kim, J.-I.; Kang, J.-H.; Seo, J.-S. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012, 22, 436–445, doi:10.1101/gr.133645.111.
113. Meka, D.P.; Müller-Rischart, A.K.; Nidadavolu, P.; Mohammadi, B.; Motori, E.; Ponna, S.K.; Aboutalebi, H.; Bassal, M.; Annamneedi, A.; Finckh, B.; et al. Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration. J Clin Invest 2015, 125, 1873–1885, doi:10.1172/JCI79300.
114. Wang, C.; Mayer, J.A.; Mazumdar, A.; Brown, P.H. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells. Breast Cancer Res Treat 2012, 133, 487–500, doi:10.1007/s10549-011-1775-9.
115. Yadav, L.; Pietilä, E.; Öhman, T.; Liu, X.; Mahato, A.K.; Sidorova, Y.; Lehti, K.; Saarma, M.; Varjosalo, M. PTPRA Phosphatase Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential. iScience 2020, 23, doi:10.1016/j.isci.2020.100871.
116. Fritsche-Guenther, R.; Witzel, F.; Sieber, A.; Herr, R.; Schmidt, N.; Braun, S.; Brummer, T.; Sers, C.; Blüthgen, N. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol Syst Biol 2011, 7, 489, doi:10.1038/msb.2011.27.
117. Lake, D.; Corrêa, S.A.L.; Müller, J. Negative feedback regulation of the ERK1/2 MAPK pathway. Cell Mol Life Sci 2016, 73, 4397–4413, doi:10.1007/s00018-016-2297-8.
118. Arkun, Y.; Yasemi, M. Dynamics and control of the ERK signaling pathway: Sensitivity, bistability, and oscillations. PLOS ONE 2018, 13, e0195513, doi:10.1371/journal.pone.0195513.
119. Tansey, M.G.; Baloh, R.H.; Milbrandt, J.; Johnson, E.M. GFRα-Mediated Localization of RET to Lipid Rafts Is Required for Effective Downstream Signaling, Differentiation, and Neuronal Survival. Neuron 2000, 25, 611–623, doi:10.1016/S0896-6273(00)81064-8.
120. Gil, Z.; Cavel, O.; Kelly, K.; Brader, P.; Rein, A.; Gao, S.P.; Carlson, D.L.; Shah, J.P.; Fong, Y.; Wong, R.J. Paracrine Regulation of Pancreatic Cancer Cell Invasion by Peripheral Nerves. J Natl Cancer Inst 2010, 102, 107–118, doi:10.1093/jnci/djp456.
121. Liu, H.; Li, X.; Xu, Q.; Lv, S.; Li, J.; Ma, Q. Role of glial cell line-derived neurotrophic factor in perineural invasion of pancreatic cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2012, 1826, 112–120, doi:10.1016/j.bbcan.2012.03.010.
122. Ban, K.; Feng, S.; Shao, L.; Ittmann, M. RET signaling in prostate cancer. Clin Cancer Res 2017, 23, 4885–4896, doi:10.1158/1078-0432.CCR-17-0528.
123. Zeng, Q.; Cheng, Y.; Zhu, Q.; Yu, Z.; Wu, X.; Huang, K.; Zhou, M.; Han, S.; Zhang, Q. The Relationship between Over-expression of Glial Cell-derived Neurotrophic Factor and Its RET Receptor with Progression and Prognosis of Human Pancreatic Cancer: Journal of International Medical Research 2008, doi:10.1177/147323000803600406.
124. Plaza-Menacho, I.; Morandi, A.; Robertson, D.; Pancholi, S.; Drury, S.; Dowsett, M.; Martin, L.-A.; Isacke, C.M. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 2010, 29, 4648–4657, doi:10.1038/onc.2010.209.
125. Morandi, A.; Martin, L.-A.; Gao, Q.; Pancholi, S.; Mackay, A.; Robertson, D.; Zvelebil, M.; Dowsett, M.; Plaza-Menacho, I.; Isacke, C.M. GDNF–RET Signaling in ER-Positive Breast Cancers Is a Key Determinant of Response and Resistance to Aromatase Inhibitors. Cancer Res 2013, 73, 3783–3795, doi:10.1158/0008-5472.CAN-12-4265.
126. Gattelli, A.; Nalvarte, I.; Boulay, A.; Roloff, T.C.; Schreiber, M.; Carragher, N.; Macleod, K.K.; Schlederer, M.; Lienhard, S.; Kenner, L.; et al. Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. EMBO Mol Med 2013, 5, 1335–1350, doi:10.1002/emmm.201302625.
127. White, U.A.; Stephens, J.M. The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function. Curr Pharm Des 2011, 17, 340–346.
128. Boulay, A.; Breuleux, M.; Stephan, C.; Fux, C.; Brisken, C.; Fiche, M.; Wartmann, M.; Stumm, M.; Lane, H.A.; Hynes, N.E. The Ret Receptor Tyrosine Kinase Pathway Functionally Interacts with the ERα Pathway in Breast Cancer. Cancer Res 2008, 68, 3743–3751, doi:10.1158/0008-5472.CAN-07-5100.
129. Hidalgo-Figueroa, M.; Bonilla, S.; Gutiérrez, F.; Pascual, A.; López-Barneo, J. GDNF Is Predominantly Expressed in the PV+ Neostriatal Interneuronal Ensemble in Normal Mouse and after Injury of the Nigrostriatal Pathway. J. Neurosci. 2012, 32, 864–872, doi:10.1523/JNEUROSCI.2693-11.2012.
130. Ibáñez, C.F.; Paratcha, G.; Ledda, F. RET-independent signaling by GDNF ligands and GFRα receptors. Cell Tissue Res 2020, doi:10.1007/s00441-020-03261-2.
131. Paratcha, G.; Ledda, F.; Ibáñez, C.F. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 2003, 113, 867–879, doi:10.1016/s0092-8674(03)00435-5.
132. Turconi, G.; Kopra, J.; Võikar, V.; Kulesskaya, N.; Vilenius, C.; Piepponen, T.P.; Andressoo, J.-O. Chronic 2-Fold Elevation of Endogenous GDNF Levels Is Safe and Enhances Motor and Dopaminergic Function in Aged Mice. Mol Ther Methods Clin Dev 2020, 17, 831–842, doi:10.1016/j.omtm.2020.04.003.
133. Villanueva, M.T. GDF15 tells the brain to lose weight. Nat Rev Drug Discov 2017, 16, 827–827, doi:10.1038/nrd.2017.241.
134. Bespalov, M.M.; Sidorova, Y.A.; Tumova, S.; Ahonen-Bishopp, A.; Magalhães, A.C.; Kulesskiy, E.; Paveliev, M.; Rivera, C.; Rauvala, H.; Saarma, M. Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin. J. Cell Biol. 2011, 192, 153–169, doi:10.1083/jcb.201009136.
135. Sidorova, Y.A.; Bespalov, M.M.; Wong, A.W.; Kambur, O.; Jokinen, V.; Lilius, T.O.; Suleymanova, I.; Karelson, G.; Rauhala, P.V.; Karelson, M.; et al. A Novel Small Molecule GDNF Receptor RET Agonist, BT13, Promotes Neurite Growth from Sensory Neurons in Vitro and Attenuates Experimental Neuropathy in the Rat. Front. Pharmacol. 2017, 8, doi:10.3389/fphar.2017.00365.
136. Viisanen, H.; Nuotio, U.; Kambur, O.; Mahato, A.K.; Jokinen, V.; Lilius, T.; Li, W.; Santos, H.A.; Karelson, M.; Rauhala, P.; et al. Novel RET agonist for the treatment of experimental neuropathies. Mol Pain 2020, 16, 1744806920950866, doi:10.1177/1744806920950866.
137. Ivanova, L.; Tammiku-Taul, J.; García-Sosa, A.T.; Sidorova, Y.; Saarma, M.; Karelson, M. Molecular Dynamics Simulations of the Interactions between Glial Cell Line-Derived Neurotrophic Factor Family Receptor GFRα1 and Small-Molecule Ligands. ACS Omega 2018, 3, 11407–11414, doi:10.1021/acsomega.8b01524.
138. Amirouchene-Angelozzi, N.; Swanton, C.; Bardelli, A. Tumor Evolution as a Therapeutic Target. Cancer Discov 2017, 7, 805–817, doi:10.1158/2159-8290.CD-17-0343.
139. Trupp, M.; Arenas, E.; Fainzilber, M.; Nilsson, A.-S.; Sieber, B.-A.; Grigoriou, M.; Kilkenny, C.; Salazar-Grueso, E.; Pachnis, V.; Arumäe, U.; et al. Functional receptor for GDNF encoded by the c- ret proto-oncogene. Nature 1996, 381, 785–789, doi:10.1038/381785a0.
140. Cintrón-Colón, A.F.; Almeida-Alves, G.; Boynton, A.M.; Spitsbergen, J.M. GDNF synthesis, signaling, and retrograde transport in motor neurons. Cell Tissue Res 2020, doi:10.1007/s00441-020-03287-6.
141. Ron, D.; Janak, P.H. GDNF and addiction. Rev Neurosci 2005, 16, 277–285, doi:10.1515/revneuro.2005.16.4.277.